Meriofert Kit (Luteinising Hormone (Human), Follicle-Stimulating Hormone)

Meriofert Kit contains gonadotropins that act on the reproductive endocrine pathway to facilitate follicular development and ovulation.

• Induction of ovulation in assisted reproductive technology: promotes follicle growth and ovulation for IVF cycles.
• Treatment of infertility due to anovulation: restores ovulatory cycles in women with hormonal insufficiency.
• Controlled ovarian stimulation: enables precise dosing to obtain multiple mature oocytes for assisted conception.

• Human luteinising hormone and follicle‑stimulating hormone bind to their respective LH and FSH receptors on ovarian granulosa and theca cells. This activation stimulates intracellular cyclic AMP pathways, leading to follicular maturation, estrogen synthesis, and ultimately ovulation. The coordinated action of both hormones mimics the natural pituitary surge required for successful oocyte development.

Adverse reactions may occur with any gonadotropin therapy.

Common Side Effects

• Injection site pain or erythema: mild discomfort at the injection site.
• Headache: transient, often resolves without intervention.
• Nausea: mild gastrointestinal upset.
• Abdominal bloating: sensation of fullness or distension.
• Mild ovarian hyperstimulation: excessive ovarian response without severe complications.

Serious or Rare Side Effects

• Ovarian hyperstimulation syndrome (OHSS): severe fluid shift, abdominal pain, and potential thromboembolic events.
• Multiple pregnancy: increased risk of twins or higher-order gestations.
• Allergic reaction: rash, itching, or anaphylaxis.
• Thromboembolic events: rare clot formation.
• Ectopic pregnancy: implantation outside the uterus.

Use of Meriofert Kit requires careful clinical monitoring.

• Patient selection: assess ovarian reserve and prior response to stimulation.
• Monitoring: perform serial ultrasound and estradiol measurements during treatment.
• OHSS risk: adjust dose or discontinue if signs of hyperstimulation appear.
• Pregnancy testing: confirm absence of pregnancy before initiating therapy.
• Contraindications: avoid in active ovarian cysts, uncontrolled thyroid disease, or malignancy.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Gonadotropin therapy may be influenced by other medications.

Major Interactions (Avoid)

• GnRH agonists or antagonists: may alter LH/FSH dynamics and affect efficacy.
• High‑dose estrogen therapy: can suppress endogenous gonadotropin response.

Moderate Interactions (Monitor Closely)

• Anticoagulants: increased risk of ovarian hemorrhage during stimulation.
• Thyroid hormone replacement: ensure euthyroid status to optimize response.
• Corticosteroids: may affect ovarian response; monitor closely.
• Dopamine agonists: potential impact on prolactin levels and ovulation.